Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Profitability ⢠High Leverage ⢠Weak Cash Conversion PAHC is profitable and reasonably valued, but high leverage, weak free-cash-flow conversion, and dividends exceeding FCF warrant caution.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Support test ⢠Weak momentum Support Level: $34.45â$34.60; next $34.00â$34.25 Resistance Level: $35.60â$36.20; stronger $37.30â$38.25 PAHC remains bearish last month, with support at $34.45â$34.60 needing to hold to avoid further downside toward $34.00â$34.25, while a move above $35.60â$36.20 would signal improvement.
Sentiment & News
Key News Insights: ⢠Record sales ⢠Earnings beat ⢠Zoetis integration Phibro's record FY2026 sales, strong earnings beat, and Zoetis portfolio integration support positive growth momentum heading into FY2027.
AI Summary
PAHC's acquisition-driven earnings step-up is now a cash-flow-and-deleveraging test: despite strong FY2026 results, slowing FY2027 EBITDA growth, ~3x leverage, weak free-cash-flow conversion, and Brazil regulatory risk make the shares actionable only if management converts synergies into materially higher FCF and lower net debt.
Description
Phibro Animal Health Corporation manufactures and sells a range of animal health and mineral nutrition products for livestock, operating through Animal Health, Mineral Nutrition, and Performance Products segments. Its portfolio includes pharmaceutical treatments and vaccines for poultry, swine and cattle, nutritional additives and trace mineral formulations, plus specialty ingredients used in non-food industries. The company distributes products to integrators, feed manufacturers and distributors across North America, Latin America, Europe, the Middle East, Africa and the Asia Pacific from its headquarters in Teaneck, New Jersey.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | PAHC gained 11.4% over 21 trading days and 4.5% on September 2. Fiscal Q4 sales rose 5%, EPS of $0.85 beat the $0.72 consensus, and record fiscal 2026 sales plus sharply higher adjusted EBITDA support further momentum. | Closed | -7.8% |
| Sep 2 | Sep 9 | PAHC | Phibro Animal Health Corporation | Phibro Animal Health exhibits strong earnings growth, margin expansion, cash flow strength, and a 42% price surge over the last month, making it a hot short-term idea with a solid fundamental and technical growth profile. | Closed | +12.8% |